- Aan een vriend sturen
- RSS
- google +
- Versie om af te drukken
- E-mail deze pagina
Nieuws (Op het werk)
De feeds met nieuws en evenementen van Gezondheid-EU worden automatisch aangemaakt op basis van criteria van de Europese Commissie. In uitzonderlijke gevallen klopt de classificatie niet.
Minimum pricing will bring “substantial health and social benefits” says new IAS report» eurocare.org
A new report published today by IAS summarises the latest evidence on minimum pricing and rebuts some common criticisms (often from vested interest groups) of the policy.[...]Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 April 2013 (europa.eu, ) »
This page provides an overview of the opinions adopted at the April 2013 meeting of the CHMP and other important outcomes.[...]European Medicines Agency recommends approval of combined advanced-therapy product (europa.eu, ) »
The European Medicines Agency?s Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorisation for MACI (matrix-induced autologous chondrocyte implantation), an advance[...]Review of the CAP schemes providing agricultural products to school children» epha.org
This article is a contribution to DG Agriculture public consultation on the Review of the CAP Schemes Providing Agricultural Products to School Children EPHAC response to CONSULTATION ON THE REVIEW O[...][European Network for Workplace Health Promotion] Guide to good practices on chronically ill employees» epha.org
The European Network for Workplace Health Promotion (ENWHP) has released its European Guide to Good Practice on chronically ill employees. Chronic illness poses a major challenge for public health - [...]Green jobs and occupational safety and health - Just Published - EU Bookshop» europa.eu
Foresight on new and emerging risks associated with new technologies by 2020 : summary[...]European statistics on accidents at work (ESAW) - Just Published - EU Bookshop» europa.eu
Summary methodology[...]Demanding physical work associated with an increased risk of cardiovascular disease » escardio.org
Additional physical activity during leisure time in those who are already physically exhausted from their daily occupation does not induce a 'training' effect but rather an overloading effect on the [...]Working Group on the European Workforce for Health, Brussels, 12 Arpil 2013 - Presentations now available» europa.eu
European Commission - Brussels, 12 April 2013 [...]
Periodic Report Summary - CHANCE (Low-cost technologies and traditional ingredients for the production of affordable, nutritionally correct foods improving health in population groups at risk of pover»
europa.eu
ALMA MATER STUDIORUM - UNIVERSITA DI BOLOGNA Project context and objectives: Although consciousness of the relationship between diet and health is increasing among the general population, currently t[...]Committee for Medicinal Products for Veterinary Use (CVMP) Meeting of 9-11 April 2013» europa.eu
The Committee adopted by consensus a positive opinion for an initial marketing authorisation application for Equilis West Nile from Intervet International B.V. a vaccine for the active immunisation o[...]Guideline on good pharmacovigilance practices: Product-or population-specific considerations I: Vaccines for prophylaxis against infectious diseases: consultation open» europa.eu
The objective of this module is to strengthen the conduct of pharmacovigilance for vaccines. It should be noted that the overall objectives and processes of pharmacovigilance are no different for vac[...]Making safer composite materials for ship building» europa.eu
Just like any mode of transport that carries members of the public, ships are subject to strict safety regulations. These not only cover the use and maintenance of the vessel but also its constructio[...]Are ‘green jobs’ safe? » europa.eu
With pressure to reduce carbon emissions, reduce waste, increase energy efficiency and the proportion of renewable energy, the EU is set for a rapid growth in the number of `green jobs' - jobs which [...]Concept paper on the development of medicinal products for the treatment of autism spectrum disorder: consultation open» europa.eu
Autism spectrum disorders (ASDs) are a group of neurodevelopmental disabilities with symptoms typically presenting before the age of 3 years and persisting into adulthood. They are described as[...]Speech: European strategies for health and safety at work: the role of social partners» europa.eu
European Commission László ANDOR European Commissioner responsible for Employment, Social Affairs and Inclusion European strategies for health and safety at work: the role of social partners European[...]Draft guideline on the declaration of the quantitative composition / labelling of biological medicinal products that contain modified proteins as active substance: consultation open» europa.eu
Draft guideline on the declaration of the quantitative composition / labelling of biological medicinal products that contain modified proteins as active substance Draft guideline on the declaration o[...]Working conditions: Commission urges Member States to implement ILO domestic workers convention» europa.eu
European Commission Press release Brussels, 21 March 2013 The European Commission has presented a proposal for a Council Decision authorising Member States to ratify the International Labour Organisa[...]Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 March 2013» europa.eu
This page provides an overview of the opinions adopted at the March 2013 meeting of the CHMP and other important outcomes.[...]European Medicines Agency reminds companies of timeframe to submit product-information translations in Croatian» europa.eu
The European Medicines Agency reminds applicants and marketing-authorisation holders that they need to submit of translations of product information in Croatian for opinions as of April 2013.[...]Scientific guideline: guideline on the clinical development of medicinal products intended for the treatment of chronic primary immune thrombocytopenia, consultation open» europa.eu
This guideline describes the information on the clinical development to be documented when an application for a marketing authorisation for a medicinal product is made for the treatment of chronic pr[...]European Medicines Agency updates product information template to label medicines subject to additional monitoring and encourage adverse-reaction reporting» europa.eu
As part of the implementation of the European Union (EU) pharmacovigilance legislation, the European Medicines Agency has updated the product information template to allow easy identification of huma[...]Revised rules on the distribution of medicinal products in the EU» europa.eu
European Commission - General Information Major developments General Information [...]Questions and answers: New 'black symbol' for medicinal products» europa.eu
European Commission MEMO Brussels, 7 March 2013 What is the black symbol? The black symbol is an inverted equilateral black triangle to be included in product information for certain categories of me[...]Employment: Commission proposes €3.6 million from Globalisation Fund for former workers of Agile S.r.l. in Italy» europa.eu
European Commission Press release Brussels, 7 March 2013 The European Commission has today proposed to provide Italy with €3.6 million from the European Globalisation Adjustment Fund (EGF) to help 85[...]Employment: Commission proposes €3.9 million from Globalisation Fund to help former tobacco workers in Austria» europa.eu
European Commission Press release Brussels, 7 March 2013 The European Commission has today proposed to provide Austria with €3.9 million from the European Globalisation Adjustment Fund (EGF) to help [...]Peer review on Performance Management in Public Employment Services» europa.eu
Arbejdsmarkedsstyrelsen (AMS) in Denmark will host this peer review from 21-22 March in Copenhagen, Denmark.[...]Scientific guideline: Guideline on the clinical investigation of medicinal products for the treatment of Duchenne and Becker muscular dystrophy, draft: consultation open» europa.eu
Recent advances in basic and clinical research have opened new perspectives for future therapeutic options in Duchenne and Becker muscular dystrophy (DBMD). The increasing number of clinical trials t[...]Concept paper on the need to revise the guideline on the clinical development of fixed dose combinations of medicinal products regarding dossier content requirements» europa.eu
The current guideline CHMP/EWP/240/95 Rev. 1 contains a section describing the legal basis applicable to fixed dose combination (FDC) product marketing authorisation application (MAA).[...]Concept paper on the need for revision of note for guidance on clinical investigation of medicinal products for the treatment of cardiac failure, draft: consultation open» europa.eu
Chronic Heart Failure (CHF) encompasses heterogeneous groups of patients with a wide spectrum of symptoms and different causes. The CHMP Guideline on the clinical investigations of medicinal products[...]Scientific guideline: Guideline on the use of porcine trypsin used in the manufacture of human biological medicinal products, draft: consultation open» europa.eu
This guideline describes the information to be considered by the manufacturer of human biological medicinal products using porcine trypsin.[...]Scientific guideline: Concept paper on use of recovered/recycled solvents in the manufacture of herbal preparations for use in herbal medicinal products / traditional herbal medicinal products, draft: consultation open» europa.eu
This concept paper concerns the standards to be applied to recycled/recovered solvents used for extraction of herbal substances in the manufacture of herbal preparations for use in herbal medicinal p[...]Reflection paper on quality of essential oils as active substances in herbal medicinal products/traditional herbal medicinal products, draft: consultation open» europa.eu
This reflection paper applies to essential oils used as active substances in herbal medicinal products (HMPs) both for human and veterinary use and in traditional herbal medicinal products (THMPs) fo[...][Evaluation] Council discussed reform of Common Agricultural Policy (CAP) & mislabelled beef products» epha.org
Last 25-26 February, EU Agriculture Ministers held a public debate in Brussels on the direct payments regulation and the horizontal regulation within the framework of the common agricultural policy ([...]Health and Safety: Commission proposes to improve workers' protection against exposure to hazardous chemicals» europa.eu
European Commission Press release Brussels, 26 February 2013 The European Commission has proposed to better protect workers from risks linked to exposure to chemicals at the workplace. In particular,[...]Speech: "EU policy on health and safety at work: myths and facts"» europa.eu
European Commission László ANDOR European Commissioner responsible for Employment, Social Affairs and Inclusion Institute of Occupational Safety and Health 2013 conference/London 26 February 2013 Lad[...]Health and Safety: Commission proposes to improve workers' protection against exposure to hazardous chemicals» europa.eu
The Commission has proposed to amend five existing EU health and safety Directives on protection of workers from exposure to harmful chemicals to align them with the latest rules on classification, l[...]Commission proposes to improve workers' protection against exposure to hazardous chemicals» europa.eu
The European Commission has proposed to better protect workers from risks linked to exposure to chemicals at the workplace.[...]European Medicines Agency: Meeting highlights from the Committee for Medicinal Products for Human Use 18-21 February 2013» europa.eu
This page provides an overview of the opinions adopted at the February 2013 meeting of the CHMP and other important outcomes.[...]2nd meeting of the eHealth Network, Brussels, 7 November 2012 - Documents endorsed during the meeting now available» europa.eu
European Commission - 0[...]Success Stories - Award-winning innovation revolutionises vaccine production» europa.eu
A European Union (EU)-funded research project has opened up a radical new era in the world of vaccine discovery and production. Focused on veterinary vaccines, the project's work has made possible a [...]Reforms at all levels needed to take advantage from the benefits of active ageing in the workplace, says new European research» europa.eu
There must be reforms at every level to achieve the multitude of benefits gained from active ageing in the workplace. This is the key element debated in the final report of the European Policy Centre[...]Events - Collaborating for Cures-Leveraging Global Public-Private Partnerships (PPPs) to Accelerate Medical Product Development - 7 March 2013, Brussels » europa.eu
The Innovative Medicines Initiative (IMI) and Critical Path Institute (C-Path) will hold a joint event on the challenges and opportunities of public-private partnerships (PPPs). This first ever publi[...]Responses to the public consultation on a common logo for legally-operating online pharmacies» europa.eu
Responses to the concept paper submitted for public consultation concerning the implementing act on a common logo for legally-operating online pharmacies/retailers offering medicinal products for hum[...]European Agency for Safety and Health at Work - Focal Points: using the power of networking to promote work safety and health»
EU-OSHA is a network organisation. Focal points in more than 30 European countries replicate our information services and campaign activities on a national level.